As we observe a move en route for patient related healthcare and tailored medicines, new opportunities come into sight for life sciences companies. Companies also need to attempt rising R&D expenditures, deteriorating new drug pipelines, exclusive rights expiries, furious contest and stricter structural units on patient safety that concern the end result.
Augmented business decisions are the new standard thanks to fast changes. From new market entrants and regulatory restructuring to expiring patents and the growing challenge of persistent diseases, leaders in the life sciences community must discover a new course to address the changing climate for health care. IG's international Life Sciences Center brings jointly a worldwide team of professionals to help you achieve your prospective goals.